Sprifermin

Summary

Sprifermin is a recombinant human fibroblast growth factor‑18 (rhFGF‑18) being investigated as a disease‑modifying osteoarthritis drug. Administered by intra‑articular injection into the knee, it aims to stimulate cartilage regeneration and slow structural deterioration in patients with symptomatic knee osteoarthritis.

Mechanism of Action

Sprifermin mimics endogenous FGF‑18, binding to fibroblast growth factor receptors on chondrocytes, principally FGFR3. This activates intracellular signalling pathways that promote chondrocyte proliferation, extracellular matrix synthesis, and inhibit catabolic proteolytic enzymes. The net effect is increased cartilage thickness and improved homeostasis of the joint surface.

What the Research Shows

Phase‑2 data from the FORWARD trial showed that intra‑articular sprifermin (100 µg given every 6 or 12 months) produced a statistically significant increase in total femorotibial cartilage thickness over two years compared with placebo, although symptom scores (WOMAC) did not differ. A 2021 meta‑analysis of eight trials confirmed structural benefits, reporting modest gains in cartilage thickness (SMD 0.55) and volume (SMD 0.39) and favorable changes in surface morphology, while finding no improvement—and a slight worsening—in WOMAC scores versus placebo. A 2023 review highlighted the promise of sprifermin but noted mixed efficacy and the need for larger, phenotype‑targeted studies. Overall, evidence supports structural effects but remains inconclusive regarding clinical relevance.

Reported Benefits

Clinical studies consistently demonstrate that sprifermin increases cartilage thickness and volume in knees with osteoarthritis, with effect sizes ranging from moderate to large in imaging endpoints. The treatment appears to be well tolerated, with adverse‑event rates comparable to placebo. These structural gains suggest potential disease‑modifying activity, especially in patients where cartilage loss is a primary concern.

Limitations of the Evidence

The increase in cartilage thickness has not translated into clear symptom relief; WOMAC scores were unchanged or slightly worse in pooled analyses. The clinical importance of the observed structural changes is uncertain, and long‑term durability beyond two years is unknown. Evidence is limited to phase‑2 trials and meta‑analyses of relatively small studies, and no regulatory approval has been granted. Heterogeneity in OA phenotypes may explain inconsistent outcomes.

Safety Considerations

Sprifermin’s safety profile in trials was similar to placebo. The most frequently reported treatment‑emergent adverse event was arthralgia, occurring at comparable rates across active and control groups. Meta‑analytic data showed no significant increase in overall adverse events (OR ≈ 1.05). No serious safety signals have emerged, but long‑term safety remains to be fully characterised.

How It Is Administered

Sprifermin is delivered by intra‑articular injection into the affected knee. Study regimens have used three weekly injections constituting a single course, repeated either every six months or annually. Doses evaluated range from 30 µg to 100 µg per course.

Routes of Administration

Goals & Uses

• Cartilage thickness increase in knee osteoarthritisStructural / Disease ModifyingModerate
• Symptomatic relief of knee osteoarthritis (pain/function)SymptomaticLow
• Disease-modifying osteoarthritis drugDisease ModificationModerate
• Disease-modifying osteoarthritis drug (DMOAD)Disease ModificationModerate

Contraindications

• Active joint infection or septic arthritisInfectiousHigh
• Active malignancy or history of malignancy near jointOncologicHigh
• Known hypersensitivity to sprifermin or excipientsAllergyModerate
• Known hypersensitivity to sprifermin or FGF-18ImmunologicHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Active joint infectionInfectionHigh

Adverse Effects

• Anti-drug antibodies (immunogenicity)ImmunologicUncommon
• Injection site painLocalCommonPain at the injection site
• HeadacheNeurologicUncommonPain in the head or upper neck
• Joint effusion/swellingLocalUncommon
• Nasopharyngitis / upper respiratory infectionInfectiousUncommon
• Transient increase in inflammatory markersSystemicRare
• Injection site reactions (arthralgia, swelling, effusion)Local/musculoskeletalCommon

Drug Interactions

• Intra-articular corticosteroidsModerate
• Heparin / heparin-like compoundsLow
• Intra‑articular corticosteroidsModerate

Population Constraints

• Severe knee OA (KL grade 4)Disease SeverityRelative
• Patients with active or recent malignancyOncologicRelative
• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveAbsolute
• Severely immunocompromised patientsImmunologicalRelative

Regulatory Status

• European UnionInvestigationalClinical trial authorization in several EU member states.
• United StatesInvestigationalUnder IND; Phase II/III trials for knee OA.
• United KingdomInvestigationalMHRA clinical trial approval.

Not approved in any major jurisdiction; currently in Phase II/III clinical trials for knee osteoarthritis.

Evidence & Sources

• [Update Osteoarthritis]
  Journal ArticleModerateHügle T2020-01-01T00:00:00.000000Z
• Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis
  Journal ArticleHighGregori D, et al.2018-01-01T00:00:00.000000Z
• Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial
  Journal ArticleModerateHochberg MC, et al.2019-01-01T00:00:00.000000Z
• Sprifermin: Effects on Cartilage Homeostasis and Therapeutic Prospects in Cartilage-Related Diseases
  Journal ArticleModerateSong Z, et al.2021-01-01T00:00:00.000000Z
• Latest insights in disease-modifying osteoarthritis drugs development
  Journal ArticleModerateLi S, et al.2023-01-01T00:00:00.000000Z
• Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis
  Journal ArticleHighZeng N, et al.2021-01-01T00:00:00.000000Z

Frequently Asked Questions